Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL3341789 |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
activin A receptor type 1/Activin receptor type-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5903] [GtoPdb: 1785] [UniProtKB: Q04771] | ||||||||
ChEMBL | Inhibition of human ALK2 using casein as substrate in presence of 10 uM [gamma33P] ATP by radioactive assay | B | 6.94 | pIC50 | 115 | nM | IC50 | J Med Chem (2020) 63: 4978-4996 [PMID:32369358] |
ChEMBL | Inhibition of ALK2 (unknown origin) expressed in HEK293T cells after 30 mins by luciferase reporter gene assay | B | 7.57 | pIC50 | 27 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
ChEMBL | Inhibition of human recombinant human ALK2 kinase after 45 mins by liquid scintillation counting in presence of ATP [gamma-32P] | B | 7.62 | pIC50 | 24 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
ChEMBL | Inhibition of human N-terminal His-tagged TEV protease site linked ALK2 Q207D mutant (201 to 499 residues) expressed in baculovirus infected Sf9 insect cells | B | 7.62 | pIC50 | 24 | nM | IC50 | J Med Chem (2020) 63: 4978-4996 [PMID:32369358] |
ChEMBL | Inhibition of human ALK2 using casein as substrate in presence of 10 uM [gamma33P] ATP by kinase assay | B | 7.62 | pIC50 | 24 | nM | IC50 | Eur J Med Chem (2020) 200: 112417-112417 [PMID:32505849] |
GtoPdb | - | - | 7.62 | pIC50 | 24 | nM | IC50 | J Med Chem (2014) 57: 7900-15 [PMID:25101911] |
bone morphogenetic protein receptor type IA/Bone morphogenetic protein receptor type-1A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5275] [GtoPdb: 1786] [UniProtKB: P36894] | ||||||||
GtoPdb | - | - | 5.93 | pIC50 | 1171 | nM | IC50 | J Med Chem (2014) 57: 7900-15 [PMID:25101911] |
ChEMBL | Inhibition of ALK3 (unknown origin) expressed in HEK293T cells after 30 mins by luciferase reporter gene assay | B | 5.93 | pIC50 | 1171 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
activin A receptor type IL/Serine/threonine-protein kinase receptor R3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5311] [GtoPdb: 1784] [UniProtKB: P37023] | ||||||||
ChEMBL | Inhibition of ALK1 (unknown origin) expressed in HEK293T cells after 30 mins by luciferase reporter gene assay | B | 7.57 | pIC50 | 27 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
GtoPdb | - | - | 7.57 | pIC50 | 27 | nM | IC50 | J Med Chem (2014) 57: 7900-15 [PMID:25101911] |
receptor interacting serine/threonine kinase 2/Serine/threonine-protein kinase RIPK2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5014] [GtoPdb: 2190] [UniProtKB: O43353] | ||||||||
ChEMBL | Inhibition of recombinant human RIPK2 incubated for 2 hr by ADP-Glo assay | B | 7 | pIC50 | 100 | nM | IC50 | Eur J Med Chem (2020) 200: 112417-112417 [PMID:32505849] |
transforming growth factor beta receptor 1/TGF-beta receptor type I in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4439] [GtoPdb: 1788] [UniProtKB: P36897] | ||||||||
ChEMBL | Inhibition of TGFbeta1-induced TGFbeta type 1 ALK5 in HEK293T cells after 30 mins by luciferase reporter gene assay | B | 4.8 | pIC50 | 16000 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
GtoPdb | - | - | 5.52 | pIC50 | 3000 | nM | IC50 | J Med Chem (2014) 57: 7900-15 [PMID:25101911] |
ChEMBL | Inhibition of purified human ALK5 kinase after 45 mins by liquid scintillation counting in presence of ATP [gamma-32P] | B | 5.52 | pIC50 | 3000 | nM | IC50 | J Med Chem (2014) 57: 7900-7915 [PMID:25101911] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]